Show simple item record

dc.contributor.authorAhearne, Matthew
dc.date.accessioned2022-09-09T12:19:43Z
dc.date.available2022-09-09T12:19:43Z
dc.date.issued2022-05
dc.identifier.citationLim, S. H., Stuart, B., Joseph-Pietras, D., Johnson, M., Campbell, N., Kelly, A., Jeffrey, D., Turaj, A. H., Rolfvondenbaumen, K., Galloway, C., Wynn, T., Coleman, A. R., Ward, B., Long, K., Coleman, H., Mundy, C., Bates, A. T., Ayres, D., Lown, R., Falconer, J., … Goldblatt, D. (2022). Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature cancer, 3(5), 552–564. https://doi.org/10.1038/s43018-022-00364-3en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15762
dc.description.abstractPatients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the PROSECO prospective observational study ( NCT04858568 ) on 457 patients with lymphoma that received two or three COVID-19 vaccine doses. We show undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment. Moreover, 60% of patients on anti-CD20 therapy had undetectable antibodies following full vaccination within 12 months of receiving their anticancer therapy. However, 70% of individuals with indolent B-cell lymphoma displayed improved antibody responses following booster vaccination. Notably, 63% of all patients displayed antigen-specific T-cell responses, which increased after a third dose irrespective of their cancer treatment status. Our results emphasize the urgency of careful monitoring of COVID-19-specific immune responses to guide vaccination schemes in these vulnerable populations.
dc.description.urihttps://www.nature.com/articles/s43018-022-00364-3en_US
dc.language.isoenen_US
dc.subjectCOVID-19en_US
dc.subjectCOVID-19 vaccinesen_US
dc.subjectB-cell malignanciesen_US
dc.titleImmune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studyen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecord10.1038/s43018-022-00364-3en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
html.description.abstractPatients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the PROSECO prospective observational study ( NCT04858568 ) on 457 patients with lymphoma that received two or three COVID-19 vaccine doses. We show undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment. Moreover, 60% of patients on anti-CD20 therapy had undetectable antibodies following full vaccination within 12 months of receiving their anticancer therapy. However, 70% of individuals with indolent B-cell lymphoma displayed improved antibody responses following booster vaccination. Notably, 63% of all patients displayed antigen-specific T-cell responses, which increased after a third dose irrespective of their cancer treatment status. Our results emphasize the urgency of careful monitoring of COVID-19-specific immune responses to guide vaccination schemes in these vulnerable populations.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record